Advanced Glycation End Products in Uremia

Thomas Henle, Toshio Miyata

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)


The term "advanced glycation end products" (AGEs) stands for a heterogenous group of amino acid derivatives that are formed via glycation processes between peptide-bound lysine or arginine derivatives and carbonyl compounds, processes originally known from food systems as "Maillard reactions." AGEs accumulate in plasma and tissues with advancing age, diabetes, and particular renal failure. In vivo and in vitro studies indicate that AGEs represent an important class of uremic toxins. This review focuses on the chemistry behind the formation of AGEs, possible mechanisms underlying the accumulation of AGEs in uremia, clinical and therapeutic implications, and possible nutritional consequences.

Original languageEnglish
Pages (from-to)321-331
Number of pages11
JournalAdvances in Renal Replacement Therapy
Issue number4
Publication statusPublished - 2003 Oct


  • Advanced glycation end products
  • Uremia


Dive into the research topics of 'Advanced Glycation End Products in Uremia'. Together they form a unique fingerprint.

Cite this